nogapendekin alfa inbakicept-pmln (Anktiva)

Indications

• for use with BCG for the treatment of aduls with BCG-unresponsive nonmuscle invasive bladder cancer

Contraindications

• pregnancy
  • major birth defects 2-4%
  • miscarriage 15-20%
• lactation:
  • no data on presence of Anktiva in human milk
  • estimated risk is low

Dosage

• for intravesicular dosing
• induction: 400 ug intravesicular with BCG once a week for 6 weeks
• maintenance: 400 ug intravesicular with BCG once a week for 3 weeks at months 4, 7, 10, 13 & 19
• if complete response at >= 25 month 25 months, additional maintenance doses with BCG once a week for 3 weeks at months 25, 31, & 37 (optional)

* instill intravesically only after dilution

* total time from vial to instillation completion should be < 2 hours

Adverse effects

• >= 15%
  • increased serum creatinine, increased serum potassium
  • dysuria, hematuria, urinary frequency, urinary urgency, urinary tract infection
  • musculoskeletal pain, chills, pyrexia

Mechanism of action

• IL-15 receptor agonist

More general terms

• antineoplastic agent (chemotherapeutic agent)